Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Financial Markets

US FDA issues 3 Form 483 observations to Gland Pharma's Pashamylaram facility

Gland Pharma said that the United States Food and Drug Administration (US FDA) has conducted an un-announced inspection of the company's Pashamylaram Facility at Hyderabad for good manufacturing practices (GMP).

By: business-standard.com

Aug 05 2024
0
0 Views

US FDA issues 3 Form 483 observations to Gland Pharma's Pashamylaram facility

US FDA issues 3 Form 483 observations to Gland Pharma's Pashamylaram facility

Related

Affle PAT climbs 31% YoY to Rs 87 crore in Q1 FY25

Glenmark Life Sciences Ltd leads gainers in 'A' group

Arrow Greentech Ltd leads gainers in 'B' group

Pound speculators slightly reduce net long positions

US FDA issues 3 Form 483 observations to Gland Pharma's Pashamylaram facility

Why SBI stock fell 5% after Q1 result? Buy, sell, hold? Check strategy here

Asian Markets Sell-Off: Nikkei tanks 13%, Kospi 5% amid US recession fears

Sheela Foam Q1 PAT rises 7% YoY to Rs 46 cr

VRL Logistics standalone net profit declines 60.41% in the June 2024 quarter

Mukand consolidated net profit declines 21.36% in the June 2024 quarter

Devyani International consolidated net profit rises 156.04% in the June 2024 quarter

Empire Industries standalone net profit rises 58.33% in the June 2024 quarter

Affle PAT climbs 31% YoY to Rs 87 crore in Q1 FY25